ANIMATION

HuLuc 63

PDL BioPharma asked XVIVO to show how a novel humanized antibody, HuLuc 63, appears to induce anti-tumor effects by binding to a protein expressed only on the surface of myeloma cells. This initiates antibody-dependent cytotoxic activity which targets myeloma cells while leaving healthy cells intact.

Client


PDL BioPharma

I was impressed by the ability of the XVIVO team to transform all the structural information and the very detailed sequence of molecular events that I assembled in a story-board into a visually pleasing work of art.

Alain Viel PhD, Senior Lecturer and Director of Undergraduate Research in Molecular and Cellular Biology, Harvard University